🚀 SOPHiA GENETICS launches the New Generation SOPHiA DDM™ Platform! Our new generation platform integrates the latest advancements in #data processing and technology, offering our customers an elevated experience and enhanced capabilities. As cancer cases continue to rise globally, our dedication to driving #innovation in data-driven medicine is stronger than ever. With over 1.8 million genomic profiles analyzed and nearly 30,000 analyses conducted monthly, the Platform's data processing has surged. The new SOPHiA DDM™ Platform features a web-based architecture that processes data more efficiently, leveraging microservices and the latest cloud computing and GPU technologies from NVIDIA and Microsoft. “Our decentralized, multimodal analytics platform supports customers and helps break data silos by creating a global community where knowledge is safely and securely shared amongst users. The new generation of our SOPHiA DDM™ Platform is revolutionizing the user experience by blending our powerful AI #algorithms with multimodal data to produce meaningful insights to further the field of precision medicine,” says Zhenyu Xu, Chief Scientific Officer, SOPHiA GENETICS. Abhimanyu Verma, Chief Technology Officer, SOPHiA GENETICS, added, “We pride ourselves on adapting our technology to meet our customers’ needs. As the technology infrastructure at most healthcare organizations worldwide has evolved, we are thrilled to continue to provide best-in-class technology and set them up for success. This new generation of our platform will allow us the flexibility to respond quickly to our customer’s evolving needs and introduce new features faster, and more efficiently.” Read the full #PressRelease on our website: https://loom.ly/VmhfcIw #DataDrivenMedicine #AIforHealthcare #Media #TechNews #HealthNews NVIDIA Healthcare, Microsoft for Healthcare
SOPHiA GENETICS
Biotechnologieforschung
Democratizing Data-Driven Medicine, Together!
Info
SOPHiA GENETICS is the creator of SOPHiA DDM™, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different modalities. The SOPHiA DDM™ Platform enables healthcare institutions to get quick, robust insights from their data. We apply our technology to areas such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support research and drug development efforts. SOPHiA GENETICS' data-sharing methodology also helps researchers and healthcare professionals work together as a community by sharing and leveraging patterns identified via artificial intelligence and machine learning. Our universal platform is designed to improve as we analyze more data over time. The SOPHiA DDM™ Platform is one of the largest technology-agnostic networks of connected healthcare institutions worldwide and is currently used by more than 750 hospital, laboratory, and biopharma institutions globally. ___________ SOPHiA GENETICS Community Guidelines We value the insights and perspectives of all our members. To ensure a constructive environment, we kindly ask everyone to adhere to the following guidelines: - Respectful interactions: treat everyone with respect and courtesy. - Constructive sharing: contribute comments and ideas that are relevant and add value to the conversation. - Stay on-topic: ensure your comments are relevant to the post or discussion. - Avoid inappropriate content: refrain from posting content that is unethical, hateful, offensive, speculations about our stock prices or financial discussions that are not in the scope of the social media platform. - No spam or solicitations: for business inquiries or other topics, kindly use the 'Contact Us' section on our official website. - Moderation rights: we reserve the right to remove comments that do not align with our guidelines, principles and values. By participating in our community, you agree to these guidelines.
- Website
-
http://www.sophiagenetics.com/
Externer Link zu SOPHiA GENETICS
- Branche
- Biotechnologieforschung
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Rolle
- Art
- Privatunternehmen
- Gegründet
- 2011
- Spezialgebiete
- Bioinformatics, Algorithms, genomics, big data, clinical, artificial intelligence, AI, Machine Learning, Deep Learning, Oncology, Cancer, ctDNA, Liquid Biopsy, Data-Driven Medicine, Precision Medicine und AI in Healthcare
Orte
-
Primär
La Pièce 12
Rolle, 1180, CH
-
185 Dartmouth St
Floor 5
Boston, Massachusetts 02116, US
-
Technopole Izarbel 158 allée Fauste d’Elhuyar
Bidart, 64210, FR
Beschäftigte von SOPHiA GENETICS
Updates
-
📣 More good news from SOPHiA GENETICS! We’re thrilled to announce the validation of a novel clinical trial assay in collaboration with Boundless Bio and Precision For Medicine at the World Clinical Biomarkers & CDx 2024 event. “The work we’ve done with SOPHiA GENETICS over the last two years to develop ECS is vital to identify patients with ecDNA amplified tumors for our POTENTIATE clinical trial of BBI-355,” said Peter Krein, PhD, Ph.D., Senior Vice President of Precision Medicine at Boundless Bio. “The capabilities that SOPHiA GENETICS provides, from assay development to clinical trial use, help enable this first-in-human precision medicine clinical trial.” “We are excited to see our SOPHiA DDM™ Platform’s capabilities continue to be delivered across the clinical trial continuum through our ground-breaking collaboration with Boundless Bio. We are very excited at the prospect of contributing to meaningful clinical advances for patients with ecDNA-driven oncogene amplified cancers,” said Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. “Working side-by-side with Boundless Bio and SOPHiA GENETICS, Precision for Medicine has generated a novel and seamless platform unlike any other that enables a new model for clinical trial testing,” said Darren W. Davis, PhD, Senior Vice President, Precision for Medicine. Learn more about our collaboration during the World Clinical Biomarkers & CDx event in Boston on September 5, 2024: https://loom.ly/FbQKPO0 Read our #PressRelease: https://loom.ly/9SYUiqM #PrecisionMedicine #DataDrivenMedicine #ClinicalTrials #Innovation #Oncology
-
Join us at #ECP2024 in Florence for an exciting morning of real-world insights! 📅 September 10th, 08:30 to 09:30 AM Save the date and meet Stefano Cheloni to discover how you can harness the power of the SOPHiA DDM™ Platform to unlock data insights in lung cancer. Find out more about our booth at #ECP: https://loom.ly/Xnz_Hrc #PrecisionMedicine #RealWorldData #Genomics #DataDrivenMedicine #Oncology
-
🚀 We have Big News to share! The New Generation SOPHiA DDM™ Platform is here, and it's set to redefine precision medicine! 💻 The New Generation SOPHiA DDM™ Platform is designed to improve your user experience with enhanced data analysis, lightning-fast navigation, novel features, and unparalleled scalability to reach new horizons in data-driven medicine. 💡What's new? • A transition to a web-based architecture, enabling rapid analysis turnaround time for users with increased data processing • A single workspace to host all modules, applications, and features • A modular architecture empowering scalability to support new technologies with larger data sets such as whole genome sequencing (WGS), measurable residual disease (MRD), liquid biopsy and multimodal applications. • A seamless experience to operate between research use only (RUO) and diagnostic (Dx) mode, with the latest EU IVDR certification. ➡️ Interested in discovering how we're empowering healthcare professionals and clinical researchers globally to push the boundaries of what's possible? 🔗 Learn more and try the New Generation SOPHiA DDM™ Platform today: https://loom.ly/FyuU78Q #NewGenSOPHiADDM #PrecisionMedicine #DataDrivenMedicine #AIinHealthcare
-
Ross Muken, our Chief Financial Officer and Chief Operating Officer, just wrapped up an exciting fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City! 🔥 He delivered insights into the future of healthcare, innovation, the certification of our SOPHiA DDM™ Platform under IVDR, and how SOPHiA GENETICS continues to lead the charge in data-driven medicine. 🎧 Missed it? Don’t worry — you can catch the full replay on our Investor Relations website: https://loom.ly/i1bXi0A #Innovation #Healthcare #DataDrivenMedicine #AIforHealthcare #Leadership #NYC
-
🔔 1 hour left! Join us from anywhere in the world as Ross Muken, CFO and COO of SOPHiA GENETICS, hosts a fireside chat at the 22nd Annual Morgan Stanley Healthcare Conference in NYC.
🗓️ Mark your calendars! Ross Muken, CFO and COO of SOPHiA GENETICS, will host a fireside chat at the 22nd Annual Morgan Stanley Healthcare Conference in New York City on September 4th. Join us virtually between 1:50 to 2:25 PM EDT / 7:50 to 8:25 PM CEST to learn how we are making strides in democratizing data-driven medicine. Register for the event on our Investor Relations website: https://loom.ly/i1bXi0A #CorporateNews #DataDrivenMedicine #PrecisionMedicine #MorganStanley #HealthcareInnovation Morgan Stanley
-
We are at World Clinical Biomarkers & CDx Boston! Join us there to discover the exciting and innovative work SOPHiA GENETICS and Boundless Bio are doing to advance the development of ecDNA-directed therapies. 📅 September 5th, 03:10 PM, Track A Hear from our great speakers: Julien PONTIS, Technical Product Manager and Lead Data Scientist, SOPHiA GENETICS Peter Krein, PhD, Vice President of Precision Medicine, Boundless Bio David Lu , Director of Precision Medicine, Boundless Bio See you there! #WorldCB&CDxBoston #PrecisionMedicine #AIforHealthcare #DataDrivenMedicine #Oncology
-
📣 Don't miss our live webinar! Join us next week on September 10th 15:00 CEST / 09:00 EDT for a live interactive webinar with Frontline Genomics! In this webinar, we will demonstrate how to better handle the complexity of NGS data analysis and variant interpretation, to confidently assess genetic variants predisposing to cancer. Attendees will learn more about novel enhanced tools for hereditary cancer research, exploring real-life application examples from two major European Cancer Institutes. 💡What will you learn? - Analytical performance results of a study conducted in collaboration with a UK hospital, based on a set of challenging clinical samples and the implementation of SOPHIA DDM™ Hereditary Cancer Solution (HCS) v2.0, at the European Institute of Oncology. - Explore the guideline-driven content, enhanced features and streamlined workflow of SOPHIA DDM™ Hereditary Cancer Solution (HCS) v2.0. - Discover improved analytical capabilities for detection of copy number variants (CNVs), Alu insertions, Boland insertions and PMS2/PMS2CL gene conversion. Don't miss it! Register here: https://loom.ly/_FIuVzQ #HereditaryCancer #Oncology #CancerResearch #Webinar #DataDrivenMedicine
-
📣 We are excited to announce that SOPHiA GENETICS has achieved a perfect 5-star rating in our recent customer satisfaction survey! Customers from around the globe—EMEA, NORAM, and LATAM—have shared their appreciation for our responsive and dedicated teams. At SOPHiA GENETICS, we are committed to being a customer-centric company, where excellence is a cornerstone of our mission. Your trust drives us to continuously improve and innovate, ensuring that we deliver the best possible experience to every customer, every time. This great feedback highlights the efforts of our teams led by Nady Rizk, our Head of Customer Services: Christina Gkintzou | Abdel Khouja | Janaalzen S. | Manuel deBettencourt | Anthony Sader | Maxime Vallée, PhD | Thomas Geffroy | Camila Marques | Elliot Martin | Francesca Bomba | Kyu Park #CustomerCentric #Teamwork #WorkCulture #Innovation #DataDrivenMedicine
-
🇧🇷 Moments from #CBGM 2024 in Cuiabá, Brazil! The SOPHiA GENETICS team had amazing three days filled with insightful meetings and idea exchanges with customers, partners, and prospects. We brought the fun with our SOPHiA DDM™ memory card game, sponsored the Best Poster Presentation, and created buzz with our Instagram wall. And who could forget the refreshing ice cream from our personalized cart? 🍦 We are delighted that so many participants enjoyed playing our interactive game and learned about our solutions. Thank you for making this event unforgettable. See you next year! #DataDrivenMedicine #Genomics #HealthcareInnovation #Brazil
Ähnliche Seiten
Finanzierung
Letzte Runde
Fremdkapital nach Börsengang15.000.000,00 $
Investor:innen
Perceptive Advisors